New research suggests that dietary interventions could help reduce the incidence and intensity of bipolar disorder. Arachidonic acid, a polyunsaturated omega-6 fatty acid, could be a key driver of bipolar disorder. Bipolar disorder is a mental health condition characterized by intense bouts of manic highs and depressive lows that can disrupt a person’s life. The condition is believed to be related to genetic factors, but a new study presents evidence that low levels of arachidonic acid may also play a role in the development of bipolar disorder.
The study found that higher levels of arachidonic acid are correlated with a lower incidence of bipolar disorder. The researchers used publicly available metabolomic data from European individuals to identify 33 metabolites associated with bipolar disorder, most of which were lipids. The study also found a genetic connection to the FADS1/2/3 gene cluster, which is known to be a strong risk factor for bipolar disorder and plays a role in the conversion of linoleic acid into arachidonic acid.
Dietary intervention could potentially play a role in reducing the risk of bipolar disorder, particularly among those with a family history of the condition. Arachidonic acid is obtained through diet and found in foods like seafood, eggs, and meat. It can also be synthesized from dietary linoleic acid in nuts, seeds, and oils. Optimal levels for arachidonic acid are still unknown, but lower levels have been associated with an increased risk of psychiatric disorders like bipolar disorder.
The study’s findings suggest that arachidonic acid plays an important role in brain development and functioning, but more research is needed to understand how it may mediate the risk of bipolar disorder. The National Institutes of Health estimates that about 4.4% of American adults experience bipolar disorder at least once in their lives. Bipolar disorder has three types: Bipolar I disorder, Bipolar II disorder, and Cyclothymic disorder. If the study’s findings are further verified, they may provide clinicians with biomarkers for diagnosing bipolar disorder and guiding treatment options in the future.
